HCC has a unique tumor microenvironment that is immunosuppressive, allowing the tumor to avoid detection by the immune system.[13] This immunosuppressive setting is influenced by the existence of specific immune cells, referred to as tumor‐infiltrating lymphocytes, which encompass CD8‐positive cytotoxic T cells, as well as the presence of immune checkpoint molecules like programmed death‐ligand 1 (PD‐L1).[14] In order to address this issue, the utilization of two monoclonal antibody drugs, namely atezolizumab and bevacizumab, has been incorporated into the treatment of HCC. The gene discussed is CD274; the disease is hepatocellular carcinoma.